Case Presentation {#sec1_1}
=================

A 35-year-old Hispanic woman was admitted to hospital with worsening of bilateral lower extremity swelling for 4 days. Her present medical illness started 1 year ago, and 2 weeks prior to this admission she was seen by her primary care physician who added diuretics to her current treatment (enalapril and hydrochlorothiazide). However, the swelling worsened and prompted her to visit an emergency room. Her medical history included well-controlled hypertension (unknown duration) and non-insulin-dependent diabetes mellitus which was diagnosed 2 years ago and managed with metformin. She reported decreased exercise tolerance limited by tiredness. She also reported intermittent diarrhea triggered by certain foods like white bread for almost 1 year. Review of the system was positive for hair loss, loss of appetite, cold intolerance, and weight loss of 16 pounds in the previous 6 months. She denied fever, shortness of breath, orthopnea, cough, joint pain, dizziness, paresthesia, dysuria, periorbital swelling, and rash. There was no history of tobacco, alcohol, and drug use and she had no known drug or food allergies. Her home medication included enalapril, hydrochlorothiazide, and metformin. Her mother had a history of hypothyroidism. She came to the United States 20 years ago from Guatemala. On physical examination, she appeared mildly anxious with stable vitals and adequate oxygen saturation on ambient air. Her BMI was 33. On examination, she had hyperkeratotic skin involving bilateral palms and soles along with 2+ bilateral pitting edema up to the level of the thigh. The rest of the physical examination, including cardiovascular, pulmonary, neurological, and abdominal, was completely normal. There were no palpable lymph nodes on physical examination. In the first set of investigations in the emergency room, she was found to have microcytic anemia with hemoglobin of 8.9 g/dL, mean corpuscular volume of 72.6 fL, leukocytosis of 17,000 k/UL with neutrophils of 84%, hypokalemia 2.8 mEq/L, hypoalbuminemia 2.4 mg/dL, and thyroid-stimulating hormone of 7.34 mIU/L (Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"}). Urine analysis and initial chest X-ray were completely normal. During hospitalization, she underwent further investigations to delineate the etiology of peripheral edema, hypoalbuminemia, and diarrhea that included an echocardiogram, which showed ejection fraction of 72%, concentric remodeling, hyperdynamic left ventricle, and trivial pericardial effusion. Ultrasound of the abdomen and pelvis showed mild hepatomegaly, mild fatty infiltration, cholelithiasis, and fibroid uterus, respectively. Ultrasound of the lower extremity showed absence of deep venous thrombosis. For evaluation of anemia and low albumin level, she underwent small bowel enteroscopy and colonoscopy that showed gastric mucosal atrophy and diverticulosis. Gastric biopsy revealed *Helicobacter pylori* gastritis for which she was started on triple therapy (amoxicillin, clarithromycin, and metronidazole). Stool workup was positive for *Strongyloides* and she was treated with ivermectin. Further workup for anemia showed no evidence of underlying hemoglobinopathy and an elevated ferritin level was deemed as acute-phase reactant. Her elevated level of TSH was secondary to subclinical hypothyroidism. On subsequent days, she started spiking fever with tachycardia and hypotension. Hence, a computed tomography (CT) scan of the chest and abdomen was performed that showed bilateral patchy areas of airspace disease, mediastinal lymphadenopathy, splenic lesion of 5.3 × 3.7 cm; a space-occupying lesion or splenic abscess could not be excluded. Septic workup was sent, and she was started on broad-spectrum antibiotics. CT-guided splenic biopsy performed by an interventional radiologist showed fragments of splenic tissue with marked neutrophilic infiltrate and no evidence of metastatic carcinoma or lymphoma was found. Gram stain showed rare gram-negative bacilli; however, no growth was identified. Bone marrow biopsy was performed suspecting hemophagocytic lymphohistiocytosis or hematologic malignancy. Her hospital course further complicated with respiratory failure necessitating mechanical ventilation, persistent fever, hemodynamic instability, and refractory shock requiring multiple pressor support. Despite all efforts, she remained severely acidotic and succumbed to death on the 13th day of hospitalization. The bone marrow biopsy reported after her demise showed bone marrow infiltration by large pleomorphic atypical lymphocytes, which occupied paratrabecular areas, consistent with malignant T-cell lymphoma. Similarly, postmortem examination of the spleen, pelvic, and paratracheal lymph nodes supported the findings of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). This case shows that lethal refractory distributive shock is not always due to failure in treating resistant bacteria; rather, it could be due to an underlying undiagnosed immunocompromised state which mounts a weak immune response against an offending agent.

Discussion {#sec1_2}
==========

In general, non-Hodgkin lymphomas originate from B lymphocytes in 85--90% of cases and 10--15% of cases originate from T cells and natural killer (NK) cells. T-cell malignancies derived from precursor or immature T cells form leukemia-lymphoblastic T-cell lymphomas, whereas mature T lymphocytes or NK cell malignancies give rise to peripheral T-cell lymphomas (PTCL). According to the World Health Organization (WHO) Classification of Tumors, peripheral T cells/NK cells comprise 22 different entities categorized according to clinical presentation as primary nodal, primary extranodal, primary cutaneous, and disseminated leukemic forms, as shown in Table [3](#T3){ref-type="table"}.

PTCL-NOS represents the most common subtype and accounts for 26% of all PTCL \[[@B1]\]. It is commonly seen in the Asian and Caribbean region, slightly predominant in men, age \> 55 years, and associated with underlying infection with viruses, including Epstein Barr virus (EBV), human immunodeficiency virus (HIV), and human T-cell leukemia virus-1 \[[@B2], [@B3], [@B4]\]. The clinical manifestation consists of B symptoms, including fever, generalized lymphadenopathy, fatigue, and unexplained weight loss. Occasionally, pruritis, eosinophilia, and hemophagocytic syndrome can be presenting features of the disease \[[@B5]\]. Disseminated disease including bone marrow involvement is seen in approximately half of the cases at the time of presentation. The skin and gastrointestinal tract represent the most commonly affected extranodal sites. Comprehensive physical examination including lymph nodes, spleen, and liver is warranted at the time of initial presentation. Diagnosis of PTCL-NOS requires a combination of high clinical suspicion and histopathological techniques. Excisional lymph node biopsy remains the cornerstone of diagnosis \[[@B6]\]. Needle biopsy guided by imaging is not recommended. After histological diagnosis is made, CT/positron emission tomography imaging and bone marrow biopsy should be performed to determine the extent and progression of the disease. Routine blood tests should include assessment of blood count, beta2-microglobulin, and lactate dehydrogenase (LDH) for prognostic purposes. Testing for HIV, EBV, human T-cell leukemia virus, and hepatitis B and C can also be done to determine the causation of the disease. The International Prognostic Index (IPI) is used to assist in determining prognosis before therapy and includes age, serum LDH level, number of extranodal sites, disease stage, and performance status. Patients often present with unfavorable features including B symptoms, elevated LDH levels, high tumor burden, advanced disease (stage III or IV), and poor performance status. Approximately 50--70% of patients present with a high or high-intermediate IPI score. New prognostic models focusing on bone marrow involvement have been developed but have not been validated yet \[[@B7]\]. Treatment of PTCL-NOS should include prompt diagnosis, aggressive treatment, and vigilant surveillance since it has a fulminant course. Aggressive chemotherapy in the early course of the disease has shown better outcomes. Multiagent chemotherapy with R-CHOP (rituximab, cyclophosphamide, hydroxydoxorubicin, Oncovin® \[vincristine\], prednisone) is the standard regimen, followed by radiotherapy in cases of stage I--II disease with an overall response rate higher than 60%. Given the poor outcome with the R-CHOP regimen, it seems that integration of radiotherapy is a reasonable approach despite a 5-year overall survival of only 20--30% \[[@B8]\]. Many other novel agents, including denileukin diftitox-, gemcitabine-, and bortezomib-based chemotherapy, have shown optimal response rates between 30 and 60%; however, a detailed explanation is beyond this review \[[@B9]\]. Combination of chemotherapy and autologous/allogenic stem cell transplant has shown survival rates of 40%, but it is associated with significant morbidity \[[@B10]\]. Although the outcomes vary significantly, the prognosis remains poor for high IPI scores with an estimated survival of 30% after 5 years despite aggressive management \[[@B11]\]. This case is unique in terms of its atypical presentation and mortal clinical course.

Conclusion {#sec1_3}
==========

In general, PTCL-NOS is not commonly seen in routine clinical practice and it requires a high index of suspicion for diagnosis. Although more prevalent in middle-aged men, the clinician should also suspect underlying undiagnosed lymphoma in critically ill young patients of any gender with no significant risk factors who do not respond to optimal medical therapy. Diagnosis requires tissue biopsy along with other prognostic markers such as LDH and beta2-macroglobulin. Despite aggressive treatment early in the disease course, its prognosis remains guarded.
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###### 

Pertinent laboratory data

                                             Normal range        Day 1     Day 4   Day 6
  ------------------------------------------ ------------------- --------- ------- -------
  *Hematology*                                                                     
  Hemoglobin, g/dL                           12--16              8.9       7.1     6.9
  Hematocrit, %                              42--51              28        24      23
  Mean corpuscular volume, fL                80--96              72.6      72.4    72.6
  White cell count, K/UL                     4.8--10.8           17.6      10      21
  Neutrophil, %                              40--70              84        70      58
  Lymphocyte, %                              20--50              7.9       21      32
  Platelets, K/UL                            150--400            183       149     57
  Erythrocyte sedimentation rate, mm/h       0--30               112               
  Haptoglobin, mg/dL                         30--200             514               
  Lactate dehydrogenase, U/L                 100--190            1,000             
  Serum iron, μg/dL                          65--175             37                
  Unsaturated iron binding capacity, μg/dL   112/346             115               
  Transferrin saturation, %                                      24                
  Serum ferritin, ng/mL                      13--150             5,000             
  Peripheral smear                                               normal            
                                                                                   
  *Metabolic panel*                                                                
  Sodium, mEq/L                              135--145            134       141     143
  Potassium, mEq/L                           3.5--5.0            2.8       3.4     5.0
  Bicarbonate, mEq/L                         24--30              30        29      11
  Chloride, mEq/L                            98--108             86        102     102
  Blood urea nitrogen, mg/dL                 6--20               15        16      27
  Creatinine, mg/dL                          0.5--1.5            0.8       1.0     2.9
  Calcium, mg/dL                             8.5--10.5           8.4               
  Thyroid-stimulating hormone, mIU/L         0.40--4.50          7.34              
  Free T3, ng/dL                             60--181             79                
  Free T4, μg/dL                             4.8--10.4           6.5               
  Thyroid-stimulating immunoglobulin, %      \<140               356               
  Vitamin B12 serum, pg/mL                   243--894            572               
  Vitamin D 25OH serum, ng/mL                30--100             \<4               
  Serum folate, ng/mL                        3.0--20.0           5.5               
                                                                                   
  *Hepatic panel*                                                                  
  Total protein, g/dL                        6.0--8.5            7.4       6.0     6.0
  Albumin, g/dL                              3.2--4.8            2.4       2.3     2.3
  Alanine aminotransferase, U/L              5--40               13                
  Aspartate aminotransferase, U/L            9--36               61                
  Alkaline phosphatase, U/L                  42--98              105               
  Total bilirubin/direct bilirubin, mg/dL    0.2--1.2/0.0--0.3   0.4/0.1           
  Prothrombin time, s                        9.5--12             18                
  Partial thromboplastin time, s             26--33              39                

###### 

Pertinent laboratory data (continued)

                                              Normal range   Day 1                          Day 4                                                                  Day 6
  ------------------------------------------- -------------- ------------------------------ ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  *Immunologic panel*                                                                                                                                              
  Angiotensin-converting enzyme assays, U/L   9--67                                         52                                                                     
  ANA/ANCA                                                   negative                                                                                              
  Anti DNA/anti-AMA/anti-SMA                                 negative                                                                                              
  C3 complement, mg/dL                        90--150        118                                                                                                   
  C4 complement, mg/dL                        16--47         21                                                                                                    
  Hepatitis B surface antibody                               positive                                                                                              
  Hepatitis B surface antigen                                negative                                                                                              
  Hepatitis C antibody EIA                                   negative                                                                                              
  HIV antibody                                                                              negative                                                               
  Immunoglobulin G, mg/dL                     694--1,618                                    2,151                                                                  
  Immunoglobulin A, mg/dL                     81--4,631                                     456                                                                    
  Celiac panel                                                                              negative                                                               
  JAK2 mutation                                                                             negative                                                               
  BCR/ABL                                                                                   negative                                                               
  Hemoglobin electrophoresis                                                                normal                                                                 
  Serum immunofixation                                                                                                                                             Faint bands in IgG, kappa and lambda are presented against a dense polyclonal background
  Urine immunofixation                                                                                                                                             Faint bands in IgG, kappa and lambda are presented against a dense polyclonal background
                                                                                                                                                                   
  *Microbiology*                                                                                                                                                   
  Blood cultures                              negative       negative                       negative                                                               
  Urine cultures                              negative       negative                       negative                                                               
  Gastric biopsy                                             negative                                                                                              
  Stool EIA                                                  positive for *Strongiolydes*                                                                          
  Splenic biopsy                                                                            Positive for rare gram-negative bacilli but no growth was identified   

###### 

World Health Organization classification of peripheral natural killer (NK)/T-cell lymphoma

  ----------------------------------------------------------------------------------
  *Primary cutaneous lymphoma*
  Mycosis fungoides and Sézary syndrome
  Primary cutaneous CD30^+^ T-cell lymphoproliferative disease
   Primary cutaneous anaplastic large cell lymphoma (C-ALCL)
   Lymphamatoid papulosis (LYP)
  Primary cutaneous peripheral T-cell lymphomas
   Gama-delta T-cell lymphoma
   CD8^+^ aggressive epidermotropic cytotoxic
   CD4^+^ small medium
  Nodal peripheral T-cell lymphoma (PTCL)
   Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
   Angioimmunoblastic T-cell lymphoma (AITL)
   Anaplastic large cell lymphoma (ALCL) anaplastic lymphoma kinase (ALK) positive
   Anaplastic large cell lymphoma (ALCL) ALK negative (provisional)
  Extranodal peripheral T-cell lymphoma
   Extranodal NK T-cell lymphoma, nasal type
   Enteropathy associated T-cell lymphoma (EATL)
   Hepatosplenic T-cell lymphoma (HSTL)
   Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
   Epstein Barr Virus (EBV)-positive T-cell lymphoproliferative childhood disorder
    EBV-positive T-cell lymphoproliferative childhood disease
    Hydroa vacciniforme-like lymphoma
  Widespread or leukemic
   T-cell prolymphocytic leukemia (T-PLL)
   T-cell large granular lymphocytic leukemia (T-LGL)
   Chronic lymphoproliferative disorders of NK cells (provisional)
   Aggressive NK cell leukemia
   Adult T-cell leukemia/lymphoma
  ----------------------------------------------------------------------------------
